BridgeBio Oncology Therapeutics, Inc. Logo

BridgeBio Oncology Therapeutics, Inc.

Clinical-stage biopharma developing inhibitors for genetically driven cancers.

BBOT | US

Overview

Corporate Details

ISIN(s):
KYG4444H1011
LEI:
Country:
United States of America
Address:
256 E. GRAND AVENUE, SUITE 104, 94080 SOUTH SAN FRANCISCO

Description

BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company focused on precision oncology. The company develops a pipeline of novel, bioavailable small molecule inhibitors designed to treat patients with RAS-dependent cancers and other malignancies with clear genetic drivers. Its core strategy centers on inhibiting active RAS, aiming to create transformative medicines that advance beyond current therapeutic approaches. BBOT was launched to accelerate the development of its parent company's precision oncology portfolio.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all BridgeBio Oncology Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BridgeBio Oncology Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BridgeBio Oncology Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Camurus Logo
Develops and commercializes long-acting medicines for severe and chronic diseases.
Sweden
CAMX
Candel Therapeutics, Inc. Logo
Develops viral immunotherapies to activate the immune system to fight cancer.
United States of America
CADL
Can-Fite BioPharma Ltd. Logo
Clinical-stage biopharma developing oral small-molecule drugs targeting the A3AR.
Israel
CANF
Cannabotech Ltd. Logo
Develops therapies by integrating cannabinoids and medicinal mushroom extracts.
Israel
CNTC
Cannovum Cannabis AG Logo
Licensed importer, wholesaler, and manufacturer of medical cannabis products.
Germany
27N0
Cantargia Logo
Develops antibody therapies targeting IL1RAP for cancer and inflammatory diseases.
Sweden
CANTA
Cantourage Group SE Logo
Produces and distributes EU-compliant medical cannabis from international partners.
Germany
HIGH
CAPRICOR THERAPEUTICS, INC. Logo
A clinical-stage biotech developing cell and exosome-based biologics for serious diseases.
United States of America
CAPR
A clinical-stage biotech developing regenerative medicines for heart failure.
United Kingdom
N/A
Cardiol Therapeutics Inc. Logo
Clinical-stage company developing anti-inflammatory and anti-fibrotic heart therapies.
United States of America
CRDL

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.